Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial health with extended cash runway and partnerships with major firms like Gilead and Sanofi. The Q&A section reveals management's cautious optimism and strategic trial designs, while avoiding specifics on certain aspects. The company's strategic plans, including new partnerships and financial guidance, suggest a positive outlook. Given the market cap of $1.85 billion, the stock is likely to react positively, but not dramatically, leading to a prediction of a 2% to 8% increase over the next two weeks.
Key Financial Performance
Revenue $2.8 million, all of which was attributable to our collaboration with Gilead.
R&D Expenses $74.1 million, with $8.4 million representing noncash stock-based compensation. Adjusted cash R&D spend was $65.7 million, reflecting a 7% decrease from the comparable amount in the second quarter of 2025.
G&A Expenses $17.3 million, with $7.4 million as noncash stock-based compensation. Adjusted cash G&A spend was $9.9 million, reflecting a 3% decrease from the comparable amount in the second quarter of 2025.
Cash Balance $978.7 million, providing a cash runway into the second half of 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
STAT6 degrader (KT-621): Completed healthy volunteer study ahead of schedule with impressive results. Phase Ib trial in AD patients completed dosing, with data expected in December. Initiated Phase IIb trial (BROADEN2) in AD and planning BREADTH Phase IIb asthma trial in Q1 2026.
IRF5 program: Unveiled in spring 2025 with robust preclinical data presented at the American College of Rheumatology Annual Meeting. KT-579 IND-enabling studies completed, with first clinical trial in healthy volunteers planned for early 2026.
CDK2 oncology molecular glue program: Entered into a new partnership with Gilead to advance this program, targeting breast cancer and other solid tumors.
Oral immunology pipeline: Positioned as one of the strongest in the industry, focusing on delivering novel oral treatment options for immune-inflammatory diseases. Strategic shift to immunology R&D has enabled the development of oral drugs with biologics-like activity.
STAT6 program market potential: Targeting highly prevalent Type 2 diseases like atopic dermatitis, asthma, COPD, and others. Significant opportunity due to low penetration of systemic advanced therapies like injectable biologics.
Financial performance: Revenue for Q3 2025 was $2.8 million, primarily from the Gilead collaboration. R&D expenses were $74.1 million, with adjusted cash R&D spend at $65.7 million. Cash balance of $978.7 million provides runway into the second half of 2028.
Operational efficiency: Adjusted operating expenses decreased slightly from the prior quarter. Cash runway supports multiple clinical trials and pipeline advancements.
Strategic shift to immunology: Focused R&D efforts on immunology to leverage the power of protein degradation for developing oral drugs with biologics-like activity.
Partnership with Gilead: Collaboration to advance the CDK2 oncology molecular glue program, with potential milestone payments and shared development responsibilities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company’s forward-looking statements are subject to risks and uncertainties, as highlighted in their 10-Q filing. This includes potential regulatory hurdles for their pipeline programs, such as KT-621 and KT-579, which could impact clinical trial progress and eventual approvals.
Clinical Trial Risks: The success of KT-621 and KT-579 depends on achieving key clinical milestones, including safety, efficacy, and biomarker endpoints. Any failure to meet these could delay or derail development.
Market Penetration Challenges: Despite the potential of oral therapies like KT-621, the company acknowledges low penetration of systemic advanced therapies in large patient populations, which could limit market adoption.
Competitive Pressures: The company faces competition from existing biologics and oral therapies, such as JAK inhibitors, which have established market presence despite safety concerns.
Financial Risks: The company reported a significant R&D expenditure of $74.1 million for the quarter, which, despite a strong cash runway, underscores the financial pressure of advancing multiple programs simultaneously.
Supply Chain and Operational Risks: Scaling operations to support Phase III trials and eventual commercialization could pose logistical and supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
STAT6 Program (KT-621): The company plans to share data from the BroADen Phase Ib trial in December 2025. The trial aims to confirm robust degradation in blood and skin, refine Phase IIb doses, and demonstrate biomarker and clinical endpoint impacts. The Phase IIb trial in atopic dermatitis (BROADEN2) has been initiated, with results expected by mid-2027. A Phase IIb trial in asthma (BREADTH) is planned for Q1 2026.
IRF5 Program (KT-579): IND-enabling studies have been completed, and the first clinical trial in healthy volunteers is planned for early 2026, with data expected later that year.
Gilead Collaboration: The partnership focuses on the CDK2 oncology molecular glue program, with potential applications in breast cancer and other solid tumors.
Financial Guidance: The company has a cash runway into the second half of 2028, sufficient to complete KT-621 Phase IIb trials, initiate Phase III activities, and advance KT-579 and other pipeline projects.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key characteristics of KT-621 that could enable it to show differential efficacy versus dupilumab at early time points?
A:KT-621 is the only oral drug that can block IL-4 and IL-13 signaling as well as upstream biologics. Preclinical studies have shown comparable activity to dupilumab, and Phase I healthy volunteer studies demonstrated biomarkers that were generally comparable or numerically superior to dupilumab. However, it is difficult to predict whether KT-621 will be better or worse than dupilumab.
Q:Why were two doses selected for the Phase Ib study, and how were the three doses for the Phase IIb study determined?
A:Two doses were selected for the Phase Ib study to understand the translation of healthy volunteer degradation profiles into patients. The three doses for the Phase IIb study were chosen based on data from the Phase Ib study, ensuring they were within the range studied in healthy volunteers. The approach is to evaluate a range of doses to determine maximal pharmacology, super pharmacology, and suboptimal pharmacology.
Q:What are the baseline characteristics of patients in the Phase Ib study, and how do they compare to historical dupilumab studies?
A:Baseline EASI levels in recent studies have shifted from high-20s/low-30s to mid-20s due to changes in patient populations accessing trials. Baseline TARC levels are also a factor, as there is a relationship between baseline TARC levels and reduction. However, specific baseline data for the Phase Ib study was not disclosed.
Q:How is the Phase IIb AD study powered, and what are the expectations for effect size?
A:The Phase IIb AD study is powered with approximately 200 patients across four arms (three drug, one placebo). The study is designed to show the desired effect relative to placebo and to discern dose response. The same doses will be used for both AD and asthma Phase IIb studies, with potential adjustments for Phase III.
Q:What is the rationale behind expecting a substantial number of patients in the BROADEN2 trial to be naive to advanced therapy?
A:The majority of moderate-to-severe patients do not have access to advanced systemic therapy, and patients who failed systemic therapies will not be included in the study. Additionally, the study is global, with many sites in regions where dupilumab is less accessible, increasing the likelihood of enrolling naive patients.
Q:What are the primary considerations for the asthma BREADTH trial design?
A:Details on the asthma BREADTH trial design, including endpoints and patient population, will be disclosed closer to the study's start. The plan is to use the same doses for both AD and asthma Phase IIb studies, with potential adjustments for Phase III.
Q:What are the initial targeted indications for the IRF5 program?
A:The IRF5 program targets lupus (SLE), interferon-related pathologies, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD), based on human genetics and preclinical data. More details will be shared closer to the Phase I study.
Q:How does KT-621's daily oral dosing regimen compare to dupilumab in terms of durability and patient outcomes?
A:KT-621 offers steady-state pathway blockade with once-daily oral dosing, allowing for continuous pharmacology. Dupilumab may have less continuous pathway blockade due to dosing intervals. KT-621 also allows for easier start and stop without long washout periods.
Q:What measures are being taken to control placebo response rates in the BROADEN2 trial?
A:The study employs careful protocol design, experienced site selection, proper training of raters, and close sponsor oversight to mitigate placebo response rates.
Q:How does Kymera view the competitive landscape for KT-621, and what is the role of the next-generation STAT6 degrader?
A:Kymera aims to be first and best in the market with KT-621, which is exceptionally potent and well-tolerated. Small molecule inhibitors are unlikely to match the pharmacological effect of KT-621. The focus is on flawless execution to establish KT-621 as a leading drug in the Th2 space.
Q:What are the key biomarkers for the IRF5 program, and when is data expected?
A:Key biomarkers for the IRF5 program will be disclosed closer to the Phase I study. Phase I data is expected in 2026.
Q:What is the expected role of KT-621 in the asthma treatment landscape?
A:KT-621 could address unmet needs in pediatric, adolescent, and adult patients with moderate-to-severe Th2 asthma. Its oral formulation and potential efficacy comparable to dupilumab could transform treatment by providing an alternative to injectable biologics.
Q:What are the compliance strategies for the Phase IIb study, and how does KT-621's pharmacology support adherence?
A:The study uses novel technologies to enhance adherence. KT-621's degrader mechanism allows for steady-state pharmacology, providing a cushion for occasional missed doses.
Q:Review of Unclear Management Responses
A:Management avoided providing specific baseline data for the Phase Ib study, details on the asthma BREADTH trial design, and specifics on rescue therapy in the Phase IIb study. They also refrained from setting numerical benchmarks for clinical efficacy endpoints in the Phase Ib study, citing variability and placebo effects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BREADTH Phase
BroADen study
Chief
Gilead
IIb trial
KT STAT
Kymera
Officer
Phase IIb
Phase volunteer
President Investor
STAT degradation
STAT degrader
STAT program
TARC level
Type disease
Vice President
atopic dermatitis
baseline TARC
biologics activity
biomarker
body
completion
compliance
dermatitis study
experience
lack
limitation
medicine potential
molecule inhibitor
pathway biologics
period
placebo
power
quality life
respect
skin KT
spring
study month
testament
treatment option
world
KYMR Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Unknown4-30
Despite a 20% revenue increase, the widening net loss and increased expenses are concerning. The lack of discussion on strategic initiatives or risk management in the earnings call suggests uncertainty. However, the stable cash position and growth in collaboration revenue provide a balanced outlook. Given the market cap of $1.85 billion, the stock is likely to see limited movement, resulting in a neutral prediction.
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
KYMR Slides
KYMR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
